Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Allena Pharmaceuticals Inc (ALNA)

Allena Pharmaceuticals Inc (ALNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split Globe Newswire - Tue Jul 12, 2022

NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to...

ALNA : 0.0750 (+3.16%)
Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split Globe Newswire - Tue Jul 5, 2022

NEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to...

ALNA : 0.0750 (+3.16%)
Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering Globe Newswire - Wed May 4, 2022

NEWTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to...

ALNA : 0.0750 (+3.16%)
Allena Pharmaceuticals Provides Clinical and Corporate Update Globe Newswire - Tue Jan 4, 2022

ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in...

ALNA : 0.0750 (+3.16%)
Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO Business Wire - Mon Dec 20, 2021

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, today announced the appointment of Mark J. Fitzpatrick as Chief Executive Officer (CEO)...

ALNA : 0.0750 (+3.16%)
Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference Globe Newswire - Mon Nov 15, 2021

NEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel...

ALNA : 0.0750 (+3.16%)
Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress Globe Newswire - Wed Nov 10, 2021

ALLN-346, a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced...

ALNA : 0.0750 (+3.16%)
Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease Globe Newswire - Wed Nov 3, 2021

- Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract - - Patients with gout and CKD have a serious condition with an...

ALNA : 0.0750 (+3.16%)
Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346 Globe NewsWire - Wed Sep 29, 2021

- Fourteen-day study focused on high unmet need in patients with gout and chronic kidney disease -

ALNA : 0.0750 (+3.16%)
Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment Conference Globe NewsWire - Thu Sep 9, 2021

NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop...

ALNA : 0.0750 (+3.16%)

Barchart Exclusives

Unusual Options Volume in Palantir Puts Could Signal a Stock Peak Barchart - Wed Dec 25, 12:30PM CST
A huge, unusual volume in Palantir Technologies put options may signal a near-term peak in PLTR stock. It has doubled since its Q3 earnings on Nov. 4. However, put premiums are now very high—an income play for short-sellers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot